Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked. In China, empirical evidence on the usage of...

Full description

Bibliographic Details
Main Authors: Yuting Yan, Rui Lv, Tingyu Wang, Ying Yu, Yanshan Huang, Wenjie Xiong, Yuxi Li, Weiwei Sui, Qi Wang, Wenyang Huang, Gang An, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
treatment patterns
adverse events
BTK inhibitor
discontinuation
outcome
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1184395/full

Similar Items

Similar Items